Keros Therapeutics (KROS) Accumulated Expenses (2019 - 2025)

Keros Therapeutics (KROS) has 7 years of Accumulated Expenses data on file, last reported at $16.0 million in Q4 2025.

• For the quarter ending Q4 2025, Accumulated Expenses fell 23.15% year-over-year to $16.0 million; the trailing twelve-month figure through Dec 2025 stood at $16.0 million (down 23.15% YoY), and the FY2025 full-year result was $16.0 million, down 23.15% from the prior year.
• Accumulated Expenses for Q4 2025 stood at $16.0 million, up from $15.2 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $22.2 million in Q3 2024 and bottomed at $5.5 million in Q1 2021.
• The 5-year median for Accumulated Expenses is $12.5 million (2023), against an average of $12.6 million.
• The widest annual swing landed in 2021, when Accumulated Expenses soared 87.71%; it then slumped 31.55% in 2025.
• A 5-year view of Accumulated Expenses shows it stood at $7.3 million in 2021, then surged by 73.77% to $12.8 million in 2022, then jumped by 40.5% to $17.9 million in 2023, then increased by 16.48% to $20.9 million in 2024, then retreated by 23.15% to $16.0 million in 2025.
• The last three Accumulated Expenses figures came in at $16.0 million (Q4 2025), $15.2 million (Q3 2025), and $20.0 million (Q2 2025), per Business Quant data.

Peer Comparison